☆ 4.6 Article

Real world data on light chain cardiac amyloidosis: Still a delayed diagnosis

FRONTIERS IN ONCOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Cardiac & Cardiovascular Systems

Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial

Kai-Ni Shen et al.

Summary: This study compared the efficacy of combined doxycycline and CyBorD with CyBorD alone in the treatment of cardiac light chain amyloidosis. The results showed that the addition of doxycycline did not significantly prolong progression-free survival or cardiac progression-free survival compared to CyBorD alone.

CIRCULATION (2022)

Add to Collection

Article Hematology

Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment

Morie A. Gertz

Summary: Immunoglobulin light chain amyloidosis is a plasma cell disorder that can affect multiple organs. Diagnosis requires tissue biopsy, and treatment aims to prevent amyloid deposition and organ failure. First-line therapy with daratumumab, bortezomib, cyclophosphamide, and dexamethasone is the recommended approach.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Review Pharmacology & Pharmacy

Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis

Hannah A. Blair

Summary: Subcutaneous daratumumab co-formulated with recombinant human hyaluronidase is approved for use in combination therapy for the treatment of adult patients with newly diagnosed AL amyloidosis. Daratumumab combination therapy significantly increases the proportion of patients achieving a haematological complete response and improves progression-free survival. Daratumumab represents an important first-line treatment option for patients with systemic AL amyloidosis.

DRUGS (2022)

Add to Collection

Review Hematology

The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types

Cindy Varga et al.

Summary: Systemic amyloidosis of the immunoglobulin light-chain (AL) or transthyretin type (ATTR) is a multisystem protein deposition disease that often involves the heart. Advances in diagnostics and treatments have significantly improved the prognosis for patients, with rapid identification of amyloid type and rational selection of therapy bringing about better outcomes. The incorporation of novel agents and the availability of stabilizers and RNA-interference agents have contributed to increased survival rates for both AL and ATTR patients, highlighting the importance of coordinated clinical application in managing this complex disease.

BLOOD REVIEWS (2021)

Add to Collection

Article Oncology

AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival

Michael Ozga et al.

Summary: This study revealed the association of FISH cytogenetic abnormalities with survival in AL amyloidosis patients, showing that hyperdiploidy has an impact on the prognosis of cardiac AL patients.

CANCER MEDICINE (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Cardiac amyloidosis-A review of current literature for the practicing physician

Samantha Ash et al.

Summary: Cardiac amyloidosis is a serious disease characterized by thickening and stiffening of the heart muscle walls, ultimately leading to heart failure. Significant progress has been made in the diagnosis and treatment of this condition, but prognosis still heavily relies on early detection.

CLINICAL CARDIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

Pablo Garcia-Pavia et al.

Summary: Cardiac amyloidosis is a serious infiltrative disease caused by the deposition of amyloid fibrils in the heart, which can be due to genetic variants or acquired conditions. With advances in imaging techniques, non-invasive diagnosis is now possible, showing that cardiac amyloidosis is more common than previously thought. The Working Group on Myocardial and Pericardial Disease has proposed definitions and diagnostic algorithms for cardiac amyloidosis.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Review Oncology

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021

M. Hasib Sidiqi et al.

Summary: AL amyloidosis can present with symptoms such as nephrotic range proteinuria, heart failure, peripheral neuropathy, hepatomegaly, or diarrhea, and may develop from smoldering multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS). Early diagnosis is crucial as these patients exhibit distinctive symptoms such as weight loss, edema, early satiety, and dyspnea.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Advances in Diagnosis and Treatment of Cardiac and Renal Amyloidosis

Steven Law et al.

CARDIOLOGY CLINICS (2021)

Add to Collection

Article Medicine, General & Internal

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis

E. Kastritis et al.

Summary: In patients with newly diagnosed AL amyloidosis, adding daratumumab to bortezomib, cyclophosphamide, and dexamethasone resulted in higher rates of hematologic complete response and improved survival outcomes. However, adverse events, including lymphopenia, pneumonia, cardiac failure, and diarrhea, were more common in the daratumumab group. Most deaths were due to amyloidosis-related cardiomyopathy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Oncology

Amyloidosis with Cardiac Involvement: Identification, Characterization, and Management

Faizi Jamal et al.

Summary: The review highlights the characteristics, diagnostic methods, and latest treatment advances in amyloidosis, emphasizing the importance of cardiac amyloidosis and its impact on prognosis. New imaging methods, diagnostic algorithms, and treatments adopted from multiple myeloma therapies significantly affect disease management and survival rates.

CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

Pablo Garcia-Pavia et al.

Summary: Cardiac amyloidosis is a serious and progressive infiltrative disease caused by amyloid fibril deposition in the heart. Advances in imaging techniques and diagnostic algorithms have made it possible to diagnose the condition non-invasively. Monitoring and treating cardiac amyloidosis are important in bridging the gap between research advances and clinical practice.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Review Hematology

Supportive Care in AL Amyloidosis

M. Teresa Cibeira et al.

ACTA HAEMATOLOGICA (2020)

Add to Collection

Review Hematology

When to Suspect a Diagnosis of Amyloidosis

Iuliana Vaxman et al.

ACTA HAEMATOLOGICA (2020)

Add to Collection

Article Oncology

A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis

Surbhi Sidana et al.

BLOOD CANCER JOURNAL (2020)

Add to Collection

Article Education, Scientific Disciplines

Management of AL amyloidosis in 2020

Giovanni Palladini et al.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)

Add to Collection

Editorial Material Hematology

Predicting survival in light chain amyloidosis

Giovanni Palladini et al.

HAEMATOLOGICA (2019)

Add to Collection

Article Hematology

Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay

Eli Muchtar et al.

BLOOD (2019)

Add to Collection

Review Hematology

Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis

Iuliana Vaxman et al.

ACTA HAEMATOLOGICA (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee

Merrill D. Benson et al.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2018)

Add to Collection

Article Health Care Sciences & Services

Light Chain (AL) Amyloidosis: The Journey to Diagnosis

Kristen L. McCausland et al.

PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2018)

Add to Collection

Review Cardiac & Cardiovascular Systems

Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response

Martha Grogan et al.

HEART (2017)

Add to Collection

Article Hematology

Clinical features and treatment outcome of primary systemic light-chain amyloidosis in Korea: Results of multicenter analysis

Hyun Jung Jun et al.

AMERICAN JOURNAL OF HEMATOLOGY (2013)

Add to Collection

Article Hematology

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis

Ashutosh D. Wechalekar et al.

BLOOD (2013)

Add to Collection

Article Oncology

New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

Giovanni Palladini et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection

Article Oncology

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis

A Dispenzieri et al.

JOURNAL OF CLINICAL ONCOLOGY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.